Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Obese Children Burdened by More than Weight

November 24, 2014 – 12:00 pm | Edit Post

High blood pressure and nonalcoholic fatty liver disease (NAFLD) are two emerging health problems related to the epidemic of childhood obesity. In a recent study, researchers at University of California, San Diego School of Medicine sought to determine the prevalence of high blood pressure in children with NAFLD, which places them at risk for premature cardiovascular disease.

Obese Children Burdened by More than Weight

November 24, 2014 – 12:00 pm | Edit Post

High blood pressure and nonalcoholic fatty liver disease (NAFLD) are two emerging health problems related to the epidemic of childhood obesity. In a recent study, researchers at University of California, San Diego School of Medicine sought to determine the prevalence of high blood pressure in children with NAFLD, which places them at risk for premature cardiovascular disease.

Sleep Apnea Linked to Poor Aerobic Fitness

November 24, 2014 – 9:31 am | Edit Post

People with moderate to severe obstructive sleep apnea may have an intrinsic inability to burn high amounts of oxygen during strenuous aerobic exercise according to a new study led by researchers at University of California, San Diego School of Medicine.

Sleep Apnea Linked to Poor Aerobic Fitness

November 24, 2014 – 9:31 am | Edit Post

People with moderate to severe obstructive sleep apnea may have an intrinsic inability to burn high amounts of oxygen during strenuous aerobic exercise according to a new study led by researchers at University of California, San Diego School of Medicine.

San Diego’s Antibody-Drug Conjugate Research Highlighted at #WorldADC Meeting in October

November 24, 2014 – 8:11 am | Edit Post

San Diego was host to the World Antibody Drug Conjugate (ADC) Meeting and Awards October 26-29th 2014. ADCs are an exciting new class of oncology therapeutics utilizing monoclonal antibodies conjugated to cytotoxic drugs, resulting in …

Physician-Scientist Shares his Journey to Help Those with Autoimmune Diseases

November 24, 2014 – 7:00 am | Edit Post

Professor Hugh Rosen spoke to donors about his experiences with drug discovery at a recent lecture hosted by TSRI’s Office of Philanthropy.

Researchers Discover New Type of Neuron that Plays Key Role in Nicotine Addiction

November 24, 2014 – 7:00 am | Edit Post

“If we can find a way to target those neurons in humans, maybe we can reduce the ‘high’ produced by the drug and reduce the withdrawal symptoms,” says Assistant Professor Olivier George.

Team Reveals Weak Spots in Ebola’s Defenses

November 24, 2014 – 7:00 am | Edit Post

The new study from the Ward and Saphire labs exposes how experimental drug ZMapp attacks the virus and suggests strategies to improve future therapies.

Cells’ Response to Chronic Protein Misfolding May Do More Harm than Good

November 24, 2014 – 7:00 am | Edit Post

The study from the Balch lab suggests diseases such as cystic fibrosis and Alzheimer’s can be seriously exacerbated by the body’s response, providing fundamental insights with implications for the design of new therapies.

Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference

November 24, 2014 – 5:39 am | Edit Post

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014 /PRNewswire/ – Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. ET in New York.

The live audio webcast and subsequent replay may be accessed by visiting Veracyte’s website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live webcast to ensure adequate time for any necessary software download. The webcast will be available shortly after conclusion of the presentation and archived on the company’s website for 14 days following the presentation.

About Veracyte

Veracyte (Nasdaq: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first commercial solution, the Afirma® Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment. Since launching its Afirma solution in 2011, Veracyte estimates it has helped approximately 10,000 patients with thyroid nodules avoid unnecessary surgery, reducing healthcare costs by millions of dollars. Afirma is recommended in leading practice guidelines and is covered for more than 135 million lives in the United States, including through Medicare and most commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. The company is in late product development for a genomic test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer. Veracyte is also developing a second product in pulmonology, targeting interstitial lung diseases that include idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Veracyte, Afirma, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.

Media:Tracy Morris650-380-4413 Tracy.Morris@Veracyte.com

Investors:Angeli KolhatkarBurns McClellan, Inc.212-213-0006akolhatkar@burnsmc.com  

SOURCE Veracyte